Expert Consensus on Type 2 Diabetes Remission

Abstract

Establishing remission as a clinical goal for carefully selected patients with Type 2 Diabetes Mellitus (T2DM) represents a fundamental shift from the traditional paradigm of lifelong disease management. Short disease duration, preserved C-peptide levels, and overweight or obesity are the central criteria for T2DM remission. T2DM remission may help reduce the psychological burden on patients, improve quality of life, delay disease progression, and reduce the risk of long-term complications. This consensus aims to help physicians establish standardized clinical diagnosis and treatment protocols for T2DM remission in overweight or obese patients with T2DM, and support related research to develop safer and more effective interventions. Notably, T2DM remission is conditional, reversible and population-selective, which is not universally applicable to all T2DM patients across different disease stages and healthcare settings.

Keywords

Type 2 Diabetes Mellitus / remission / consensus / delphi method / lifestyle intervention

References

[1] Chen CM, Kong LZ, editors. Guidelines for Prevention and Control of Overweight and Obesity in Chinese Adults. Beijing: People’s Medical Publishing House; 2006.

[2] Hou X, Lu J, Weng J, Ji L, Shan Z, Liu J, et al.; China National Diabetes and Metabolic Disorders Study Group. Impact of waist circumference and body mass index on risk of cardiometabolic disorder and cardiovascular disease in Chinese adults: a national diabetes and metabolic disorders survey. PLoS One. 2013; 8: e57319.

[3] Guo Y, Zhao X, Liu C, Huang Z, Zou D. A novel refined classification system for type 2 diabetes in adults: A Chinese retrospective cohort study. Diabetes Metab Res Rev. 2022; 38:e3577.

[4] Gong Q, Zhang P, Wang J, Ma J, An Y, Chen Y, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019; 7: 452-61.

[5] Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997; 20: 537-44.

[6] Pan XR, Hu YH, Li GW, Liu PA, Bennett PH, Howard BV. Impaired glucose tolerance and its relationship to ECG-indicated coronary heart disease and risk factors among Chinese. Da Qing IGT and diabetes study. Diabetes Care. 1993; 16: 150-6.

[7] Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393-403.

[8] Lindström J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, et al.; Finnish Diabetes Prevention Study Group. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3- year results on diet and physical activity. Diabetes Care. 2003; 26: 3230-6.

[9] Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary careled weight management for remission of type 2 diabetes (DiRECT): an openlabel, clusterrandomised trial. Lancet. 2018; 391:54151.

[10] Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013; 369: 145-54.

[11] Kramer CK, Zinman B, Choi H, Retnakaran R. Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes. BMJ Open Diabetes Res Care. 2016; 4: e000270.

[12] Park S, Choi SB. Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev. 2003; 19: 124-30.

[13] Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care. 2004; 27: 2597-602.

[14] Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008; 371: 1753-60.

[15] Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2013; 1: 28-34.

[16] Global report on diabetes [Internet]. World Health Organization; [cited 2016 Apr 6]. Available from: http://www.who.int/diabetes/global-report/en/

[17] Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetologia. 2021; 64: 2359-66.

[18] Rosenfeld RM, Kelly JH, Agarwal M, Aspry K, Barnett T, Davis BC, et al. Dietary Interventions to Treat Type 2 Diabetes in Adults with a Goal of Remission: An Expert Consensus Statement from the American College of Lifestyle Medicine. Am J Lifestyle Med. 2022; 16: 342-62.

[19] Sandforth A, von Schwartzenberg RJ, Arreola EV, Hanson RL, Sancar G, Katzenstein S, et al. Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS). Lancet Diabetes Endocrinol. 2023; 11: 798-810.

[20] Cinti F, Bouchi R, Kim-Muller JY, Ohmura Y, Sandoval PR, Masini M, et al. Evidence of β-Cell Dedifferentiation in Human Type 2 Diabetes. J Clin Endocrinol Metab. 2016; 101: 1044-54.

[21] Suleiman M, Marselli L, Cnop M, Eizirik DL, Luca CD, Femia FR, et al. The Role of Beta Cell Recovery in Type 2 Diabetes Remission. Int J Mol Sci. 2022; 23: 7435.

[22] Sattar N, Welsh P, Leslie WS, Thom G, McCombie L, Brosnahan N, et al. Dietary weight-management for type 2 diabetes remissions in South Asians: the South Asian diabetes remission randomised trial for proof-of-concept and feasibility (STANDby). Lancet Reg Health Southeast Asia. 2023; 9: 100111.

[23] Rubino F, Cohen RV. Effect of Diet versus Gastric Bypass on Metabolic Function in Diabetes. N Engl J Med. 2020; 383: 2390-1.

[24] Taylor R, Irvine KM, Barnes AC, Kelly TL, Clark LG, Hollingsworth KG, et al. 218-LB: Remission of Type 2 Diabetes after Weight Loss in “Normal” Weight People-The ReTUNE Study. Diabetes. 2022; 71: e71.

[25] Al-Mrabeh A, Zhyzhneuskaya SV, Peters C, Barnes AC, Melhem S, Jesuthasan A, et al. Hepatic Lipoprotein Export and Remission of Human Type 2 Diabetes after Weight Loss. Cell Metab. 2020; 31: 233-49.e4.

[26] Roncero-Ramos I, Gutierrez-Mariscal FM, Gomez-Delgado F, Villasanta-Gonzalez A, Torres-Peña JD, Cruz-Ares SDL, et al. Beta cell functionality and hepatic insulin resistance are major contributors to type 2 diabetes remission and starting pharmacological therapy: from CORDIOPREV randomized controlled trial. Transl Res. 2021; 238: 12-24.

[27] Fujihara K, Khin L, Murai K, Yamazaki Y, Tsuruoka K, Yagyuda N, et al.; JDDM Study Group. Incidence and predictors of remission and relapse of type 2 diabetes mellitus in Japan: Analysis of a nationwide patient registry (JDDM73). Diabetes Obes Metab. 2023; 25: 2227-35.

[28] Karter AJ, Nundy S, Parker MM, Moffet HH, Huang ES. Incidence of Remission in Adults With Type 2 Diabetes: The Diabetes & Aging Study. Diabetes Care. 2014; 37: 3188-95.

[29] Hocking SL, Markovic TP, Lee CMY, Picone TJ, Gudorf KE, Colagiuri S. Intensive Lifestyle Intervention for Remission of Early Type 2 Diabetes in Primary Care in Australia: DiRECT-Aus. Diabetes Care. 2024; 47: 66-70.

[30] Churuangsuk C, Hall J, Reynolds A, Griffin SJ, Combet E, Lean MEJ. Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission. Diabetologia. 2022; 65: 14-36.

[31] Anjana RM, Srinivasan S, Sudha V, Joshi SR, Saboo B, Tandon N, et al. Macronutrient Recommendations for Remission and Prevention of Diabetes in Asian Indians Based on a Data-Driven Optimization Model: The ICMR-INDIAB National Study. Diabetes Care. 2022; 45: 2883-91.

[32] Goldenberg JZ, Day A, Brinkworth GD, Sato J, Yamada S, Jönsson T, et al. Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data. BMJ. 2021; 372: m4743.

[33] Dambha-Miller H, Day AJ, Strelitz J, Irving G, Griffin SJ. Behaviour change, weight loss and remission of Type 2 diabetes: a community-based prospective cohort study. Diabet Med. 2019; 37: 681-8.

[34] Liu Y, Chen Y, Ma J, Lin J, Liu C, Li X, et al. Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025; 388: e081820.

[35] Zeng J, Gan S, Mi N, Liu Y, Su X, Zhang W, et al. Diabetes remission in drug-naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study. Diabetes Obes Metab. 2023; 25: 2878-87.

[36] McInnes N, Hall S, Hramiak I, Sigal RJ, Goldenberg R, Gupta N, et al.; REMIT-sita Collaborative Group. Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial. Diabetes Care. 2022; 45: 178-85.

[37] McInnes N, Hall S, Lochnan HA, Harris SB, Punthakee Z, Sigal RJ, et al.; REMIT-iGlarLixi Collaborative Group. Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial. Diabetes Obes Metab. 2023; 25: 3347-55.

[38] Ghusn W, Ikemiya K, Al Annan K, Acosta A, Dayyeh BKA, Lee E, et al. Diabetes Mellitus Remission in Patients with BMI > 50 kg/m² after Bariatric Surgeries: A Real-World Multi-Centered Study. Obes Surg. 2023; 33: 1838-45.

[39] Sjöström L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden Å, et al. Association of Bariatric Surgery With Long-term Remission of Type 2 Diabetes and With Microvascular and Macrovascular Complications. JAMA. 2014; 311: 2297.

[40] Barthold D, Brouwer E, Barton LJ, Arterburn DE, Basu A, Courcoulas A, et al. Minimum Threshold of Bariatric Surgical Weight Loss for Initial Diabetes Remission. Diabetes Care. 2021; 45: 92-9.